002755.SZ
002755.SZ
CNE100001X92
ASK PHARM
Loading chart...

Company Profile

Beijing Aosaikang Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of active pharmaceutical ingredients and formulations in China. It also offers digestive health products, which include pump inhibitors suitable for various digestive tract-related diseases, such as peptic ulcers, reflux esophagitis, and upper gastrointestinal bleeding; and anti-tumor products, including the treatment of non-small cell lung cancer, colorectal cancer, and breast cancer, encompassing targeted therapy, chemotherapy, endocrine therapy, and adjuvant medications. In addition, the company provides anti-infective products comprising a product defense line against bacterial and invasive fungal infections; and the chronic disease field focusing on chronic diseases requiring long-term management consisting of diabetes, osteoarthritis, thrombocytopenia, and iron overload. Beijing Aosaikang Pharmaceutical Co., Ltd. was founded in 1996 and is based in Nanjing, China.

Related stocks

600420.SS
600420.SS • China
SHANGHAI SHYNDEC PHARMACEUTICAL
8.51 CNY
1.71B USD 1Y -20.2%
605507.SS
605507.SS • China
GUOBANG PHARMA LTD
17.31 CNY
2.03B USD 1Y +7.4%
600285.SS
600285.SS • China
HENAN LINGRUI PHARMACEUTICAL
19.66 CNY
1.67B USD 1Y -11.5%
603456.SS
603456.SS • China
ZHEJIANG JIUZHOU PHARMACEUTICAL
16.31 CNY
2.14B USD 1Y -20.9%
600211.SS
600211.SS • China
TIBET RHODIOLA PHARMACEUTICAL H
36.78 CNY
1.77B USD 1Y -22.9%
300026.SZ
300026.SZ • China
CHASE SUN PHARM.
3.32 CNY
1.49B USD 1Y -10.8%
600572.SS
600572.SS • China
ZHEJIANG CONBA PHARMACEUTICAL C
4.41 CNY
1.68B USD 1Y +0.5%
1513.HK
1513.HK • China
LIVZON PHARMA
22.16 HKD
2.51B USD 1Y -35.7%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
46.0% p.a.
Max Drawdown (5Y)
-60.9%
Sharpe Ratio (5Y)
-0.02
Beta Factor
0.06
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 63.5 (Elevated multiple compression risk)
Elevated Short-Term Volatility: 3Y volatility (50.8%) is noticeably higher than the 5Y average (46.0%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (46.0% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -78.0% in the extended horizon.
ende